Acrodermatitis chronica atrophicans medical therapy: Difference between revisions
| Line 9: | Line 9: | ||
*Up to four weeks [[treatment]] with [[antibiotics]] such as [[doxycycline]] and [[penicillin]] has been recommended in acute cases.<ref name="AbererBreier1996">{{cite journal|last1=Aberer|first1=Elisabeth|last2=Breier|first2=F.|last3=Stanek|first3=G.|last4=Schmidt|first4=B.|title=Success and failure in the treatment of acrodermatitis chronica atrophicans|journal=Infection|volume=24|issue=1|year=1996|pages=85–87|issn=0300-8126|doi=10.1007/BF01780666}}</ref> | *Up to four weeks [[treatment]] with [[antibiotics]] such as [[doxycycline]] and [[penicillin]] has been recommended in acute cases.<ref name="AbererBreier1996">{{cite journal|last1=Aberer|first1=Elisabeth|last2=Breier|first2=F.|last3=Stanek|first3=G.|last4=Schmidt|first4=B.|title=Success and failure in the treatment of acrodermatitis chronica atrophicans|journal=Infection|volume=24|issue=1|year=1996|pages=85–87|issn=0300-8126|doi=10.1007/BF01780666}}</ref> | ||
*92% of [[patients]] in a study had significant reduction in level of [[antibody]] after proper [[antibiotic]] [[therapy]].<ref>{{cite journal|doi=10.2340/0001555574424428}}</ref> | *92% of [[patients]] in a study had significant reduction in level of [[antibody]] after proper [[antibiotic]] [[therapy]].<ref>{{cite journal|doi=10.2340/0001555574424428}}</ref> | ||
*[[In vitro]] investigations have been revealed [[borrelia]] susceptibility to [[antibiotics]] such as [[erythromycin]], [[ceftriaxone]] and [[Cefotaxime sodium|cefotaxime]].<ref name="MursicWilske1987">{{cite journal|last1=Mursic|first1=V. P.|last2=Wilske|first2=B.|last3=Schierz|first3=G.|last4=Holmburger|first4=M.|last5=Süß|first5=E.|title=In vitro and in vivo susceptibility ofBorrelia burgdorferi|journal=European Journal of Clinical Microbiology|volume=6|issue=4|year=1987|pages=424–426|issn=0722-2211|doi=10.1007/BF02013102}}</ref> | |||
==References== | ==References== | ||
Revision as of 12:36, 8 June 2021
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anahita Deylamsalehi, M.D.[2] Raviteja Guddeti, M.B.B.S. [3]
|
Acrodermatitis chronica atrophicans Microchapters |
|
Differentiating Acrodermatitis chronica atrophicans from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acrodermatitis chronica atrophicans medical therapy On the Web |
|
American Roentgen Ray Society Images of Acrodermatitis chronica atrophicans medical therapy |
|
Acrodermatitis chronica atrophicans medical therapy in the news |
|
Blogs on Acrodermatitis chronica atrophicans medical therapy |
|
Risk calculators and risk factors for Acrodermatitis chronica atrophicans medical therapy |
Overview
Treatment of acrodermatitis chronica atrophicans consists of antibiotics such as doxycycline and penicillin. The recommended duration for treatment is up to four weeks in acute cases.
Medical Therapy
- Antibiotic therapy is recommended in patients with acrodermatitis chronica atrophicans.[1]
- Up to four weeks treatment with antibiotics such as doxycycline and penicillin has been recommended in acute cases.[2]
- 92% of patients in a study had significant reduction in level of antibody after proper antibiotic therapy.[3]
- In vitro investigations have been revealed borrelia susceptibility to antibiotics such as erythromycin, ceftriaxone and cefotaxime.[4]
References
- ↑ Weber K, Preac-Mursic V, Neubert U, Thurmayr R, Herzer P, Wilske B; et al. (1988). "Antibiotic therapy of early European Lyme borreliosis and acrodermatitis chronica atrophicans". Ann N Y Acad Sci. 539: 324–45. doi:10.1111/j.1749-6632.1988.tb31867.x. PMID 3056202.
- ↑ Aberer, Elisabeth; Breier, F.; Stanek, G.; Schmidt, B. (1996). "Success and failure in the treatment of acrodermatitis chronica atrophicans". Infection. 24 (1): 85–87. doi:10.1007/BF01780666. ISSN 0300-8126.
- ↑ . doi:10.2340/0001555574424428. Missing or empty
|title=(help) - ↑ Mursic, V. P.; Wilske, B.; Schierz, G.; Holmburger, M.; Süß, E. (1987). "In vitro and in vivo susceptibility ofBorrelia burgdorferi". European Journal of Clinical Microbiology. 6 (4): 424–426. doi:10.1007/BF02013102. ISSN 0722-2211.